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128Progression of asymptomatic carotid stenosis
despite optimal medical therapy
Mark F. Conrad, MD, MMSc, Valy Baloum, MD, Shankha Mukhopadhyay, MS, Ashu Garg, MD,
Virendra I. Patel, MD, and Richard P. Cambria, MD, Boston, Mass
Background: Despite level 1 evidence in support of carotid endarterectomy vs medical therapy in selected asymptomatic
patients, an alternative posture is that optimal medical therapy (OMT) has not been adequately studied and that such
OMT has reduced stroke risk in asymptomatic patients to levels wherein carotid endarterectomy is no longer justiﬁed. The
goal of this study was to determine the natural history of patients with asymptomatic moderate (50%-69%) carotid artery
stenosis (AMCAS) in a contemporary cohort as a function of their associated medical therapy.
Methods: Patients with AMCAS determined by duplex ultrasound (DUS) from 2005-2006 were identiﬁed in our hospital
database. Patients were included in the cohort if they had at least one additional DUS during the 6-year follow-up
interval. Patient characteristics including medication history and lipid levels were collected. Patients were considered to
have OMT if they were on aspirin and a statin with a low-density lipoprotein level that was always <100 mg/dL. Study
end points included progression of carotid disease by DUS to severe stenosis (70%-100%), development of ipsilateral
neurologic symptoms (INS) such as stroke or transient ischemic attack, and death.
Results: There were 900 carotid arteries in 794 patients in the study cohort. The average age was 72.5 years, 77.2% had
hypertension, 59.6% had coronary artery disease, and 87.1% were on a statin throughout the study. The low-density lipo-
protein cholesterol level was always normal (<100 mg/dL) in 37.8% and accordingly, 241 (30.3%) had OMT as deﬁned
above. The 5-year actuarial survival was 81.9%6 1.3% with no advantage seen with OMT. Multivariate analysis of survival
showed statins were protective (hazard ratio [HR], 0.50; conﬁdence interval [CI], 0.34-0.73; P [ .0004). The 5-year
freedom from plaque progression was 61.2% 6 2.1% with no beneﬁt from OMT vs the control group. Multivariate
predictors of plaque progression were chronic kidney disease (HR, 2.1; CI, 1.2-3.7; P[ .009), aspirin use (HR, 1.9; CI,
1.2-3.0; P[ .01), and the use of calcium channel blockers (HR, 1.4; CI, 1.1-1.8; P[ .007). There were 90 (11.3%) patients
who developed INS during follow-up (58% of these were strokes), and the 5-year freedom from INS was 88.4% 6 1.5%.
Multivariate predictors of INS were diabetes (HR, 2.3; CI, 1.5-3.6; P [ .0002) and warfarin use (HR, 1.9; CI, 1.2-2.9;
P[ .009); while statin use (HR, 0.37; CI, 0.22-0.65; P[ .0005) was protective against symptom development.
Conclusions: At the 5-year of follow-up, OMT failed to prevent carotid disease progression or development of ipsilateral
symptoms in 45% of patients with AMCAS. (J Vasc Surg 2013;58:128-35.)In 1951, C. Miller Fisher established the association
between atherosclerotic disease of the internal carotid artery
(ICA) and the development of ipsilateral hemispheric
stroke and suggested that removal of the offending plaque
may prevent stroke.1 It is now estimated that some 6% of
Americans over 65 harbor an asymptomatic carotid artery
stenosis >50%2,3 and extracranial carotid stenosis is respon-
sible for up to 20% of anterior circulation infarcts.4,5 In
contemporary practice, the treatment of asymptomatic
patients with a >70% stenosis of the ICA with carotidthe Division of Vascular and Endovascular Surgery, Massachusetts
eneral Hospital and Harvard Medical School.
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://dx.doi.org/10.1016/j.jvs.2013.04.002endarterectomy (CEA) is supported by level-1 evidence
and current practice guidelines.6-8 Recently, convincing
data from pooled randomized trials demonstrated that
patients taking statins have a reduced risk of stroke.9,10
This improvement in medical therapy has translated to
a lower incidence of stroke in the general population where
the lifetime risk of stroke in a 65-year-old male has
decreased from 19.5% in the 1970s to 14.5% today.11
Such data have prompted some authors to conclude that
the signiﬁcant beneﬁt seen with CEA over medical therapy
in the Asymptomatic Carotid Atherosclerosis Study
(ACAS) and other trials was due to inadequate therapy in
the medical arm.4 It has even been suggested that medical
therapy should replace CEA as the standard of care for
patients with asymptomatic carotid disease.4,12-14 Alterna-
tively, there are contemporary data from the Reduction of
Atherothrombosis for Continued Health registry indicating
that carotid stenosis >70% signiﬁcantly increases stroke risk
irrespective of the fact that 70% of this cohort were on statin
medications.15 Indeed, a consistent 2% per year risk of
carotid-related stroke from high grade asymptomatic
lesions was reported in ACAS, the North American Symp-
tomatic Carotid Endarterectomy Trial (NASCET), and the
Asymptomatic Carotid Surgery Trial (ACST); and in the
later years of ACST, 80% of patients were on statins.6,16,17
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cessation, antiplatelet therapy, control of hypertension
and diabetes, and lipid lowering with statins.8,18 While
the effect of statins on the development of stroke in the
general population and to some extent in patients with
asymptomatic carotid lesions has been evaluated,9,10,19,20
the true impact of optimal medical therapy (OMT) has
not. There is consensus from practice guidelines that
asymptomatic moderate (50%-70%) carotid artery stenosis
(AMCAS) is managed medically, and inferences on the
adequacy of OMT in patients with more severe carotid
stenoses can be learned from studying OMT in this popu-
lation (especially with regard to plaque progression).
Sequential duplex ultrasound (DUS) of patients with
AMCAS is the current standard of care, in particular since
natural history studies indicate that progression of carotid
stenosis is a signiﬁcant predictor of stroke risk.21,22 The
current study was undertaken to determine if the use of
medical therapy (statins/aspirin) would stabilize moderate
internal carotid stenosis and prevent disease progression or




This protocol was approved by the Institutional Review
Board of the Massachusetts General Hospital (MGH). Its
parent company, Partners Healthcare, maintains a central-
ized clinical data registry of all patient encounters within
the system. This database, the Research Patient Data
Registry, was searched for the International Classiﬁcation
of Disease, Ninth Revision code for patients with asymp-
tomatic carotid artery stenosis (43310) who underwent
DUS at MGH from January 1, 2005 to December 31,
2006. DUS procedures were identiﬁed by the Current
Procedural Technology codes 93880 and 93882, which
are designated for unilateral or bilateral Duplex scan of
extracranial arteries. The search was limited to 2005-
2006 to ensure at least 5 years of follow-up after the index
study. This initial query yielded 6215 patients.
The results of the 6215 patients were reviewed, and
each individual carotid artery was categorized based on
the guidelines established by our Intersocietal Commission
for the Accreditation of Vascular Laboratories accred-
ited noninvasive laboratory. Patients with a moderate
(50%-69%) stenosis of at least one extracranial ICA were
identiﬁed (1372 carotids), and their medical records were
reviewed for evidence of clinical activity. Patients who did
not have at least one interval DUS study and had no ofﬁce
visits during the follow-up period were excluded because
they likely received the majority of their health care outside
of the Partners system. There were 1017 carotid arteries in
884 patients that met the Intersocietal Commission for the
Accreditation of Vascular Laboratories deﬁnition AMCAS
and had clinical follow-up at the MGH. Upon further
review of the electronic medical records, an additional
117 carotid arteries were excluded because of the presenceof INS within the 6 months prior to the index DUS or
a history of prior ipsilateral carotid revascularization.
Thus, the ﬁnal cohort consisted of patients with native,
untreated by intervention, AMCAS (Supplementary Fig,
online only).
Outcomes and deﬁnitions
Asymptomatic status. Patients were considered to be
asymptomatic if they had no ipsilateral neurologic events of
stroke, transient ischemic attack (TIA), or amaurosis fugax
within the 6 months prior to the index DUS. This is based
upon the deﬁnition used by the ACST collaborative group,
which consisted of surgeons from 126 hospitals in 30
countries and was further supported by the DEFINE
group, which stated that patients with neurologic symp-
toms older than 6 months should be considered asymp-
tomatic because the risk of recurrent stroke decreases
over time.7,23 One hundred six patients had bilateral
asymptomatic moderate stenoses. Because there was no
difference in the incidence of bilateral lesions between the
two cohorts as deﬁned below (8% OMT vs 10% control;
P ¼ NS) and the neurologic outcomes were referable to
the indexed vessel, each artery was considered separately in
the analysis.
Moderate carotid stenosis. The moderate stenosis
category corresponds to a 50%-69% diameter reduction of
the ICA. Although these criteria have undergone minor
changes, our laboratory uses the standard values in the
ICA of peak systolic velocity between 125 and 250 cm/s,
end diastolic velocity of 40-100 cm/s, and an ICA/
common carotid artery (CCA) ratio of 2.0-4.0 to deﬁne
the moderate category.8 A severe or very severe stenosis
(70%-99%) of the ICA was diagnosed by a peak systolic
velocity >250 cm/s, ICA/CCA ratio >4, and end diastolic
velocityICA >100 cm/s.
The primary end points for the study were death,
development of ISN, and plaque progression. Survival
was determined by a review of the medical record and
Social Security Death Index when necessary. The other
end points were deﬁned as outlined below.
INS. Patients who experienced an episode of stroke,
TIA, or amaurosis fugax referable to the ICA after the
date of the index DUS were considered to have become
symptomatic. All strokes were evaluated by a neurologist
and anatomic defects were conﬁrmed with computed
tomography or magnetic resonance imaging (MRI) of
the brain.
Plaque progression. Serial DUS were evaluated and
patients who were found to have changes in their peak
velocities or ICA/CCA ratio that placed them in the severe
(70%-89%), very severe (90%-99%), or occluded (100%)
categories were considered to have experienced plaque
progression.
Operative intervention. All ipsilateral procedures per-
formed on the ICA were documented including CEA,
carotid stenting, and one carotid interposition graft. The
indications for and type of operative intervention were at
the discretion of the intervening physician.
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mented low-density lipoprotein (LDL) levels <100 mg/dL
during the entire follow-up period. Since there is no way to
determine patient compliance to medication in this type of
study, LDL levels were used as a surrogate. The target level
of an LDL<100mg/dLwas chosen based upon Society for
Vascular Surgery (SVS) guidelines for the management of
carotid stenosis and the recommendation of the National
Cholesterol Education Program-Adult Treatment Panel
III.8,24 The statin dose was recorded for each patient and
was considered high based upon the reference of atorvastatin
80 mg; the doses of other statins were compared with
this according to the Food and Drug Administration
equivalency chart found at http://www.fda.gov/Drugs/
DrugSafety/ucm256581.htm. Patients in whom no lipid
levels were available (25% of the cohort) were automatically
placed in the control cohort.
Statistical analysis
Categorical demographic and clinical data are pre-
sented as the percentage prevalence in the study popula-
tion. Continuous data are presented as mean 6 standard
deviation. Univariate analysis was performed using two-
tailed t-tests for continuous variables and c2 analysis for
categorical data. All long-term outcomes with variable
follow-up including survival, freedom from plaque progres-
sion, and INS were determined using Kaplan-Meier anal-
ysis. Cox proportional hazards models were created to
identify multivariate predictors of death, plaque progres-
sion, and INS. A P value of <.05 was considered statisti-
cally signiﬁcant.
RESULTS
The study population consisted of 900 carotid arteries
in 794 patients with AMCAS. The mean age was 72.5
years. Sex was represented almost evenly between males
and females. The most prevalent comorbidities were hyper-
tension (77.2%), coronary artery disease (CAD) (59.6%),
peripheral vascular disease (56%), and diabetes (37.8%)
(Table I).
The majority of patients (693; 86.5%) were on an
aspirin and a lipid-lowering agent (698; 87.1%). This was
a statin in 96% of patients, and 133 (16.6% of all patients)
were on a high-dose statin. Three-quarters of the patients
had blood lipid levels drawn during follow-up. Among
those with lipid proﬁles, 306 had maintained an
LDL <100 mg/dL, and 81 of those maintained an
LDL <70 mg/dL. The medication and lipid data are
summarized in Table II. Two hundred forty-one (30.3%)
patients had OMT. The demographic differences between
the OMT group and the control group are summarized in
Table I. The two groups differed in that the OMT cohort
had a higher incidence of hypertension, diabetes, and
CAD.
The 5-year actuarial survival for the entire cohort was
81.9% 6 1.3% with no advantage seen with OMT
(80.5% 6 2.4% OMT vs 82.4% 6 1.5% control; P ¼ .69)
(Fig 1). Multivariate predictors of death included age,contralateral occlusion, CAD, COPD, plavix use, and
chronic kidney disease (CKD); aspirin was protective
(Table III).
The mean DUS follow-up was 3.6 years with a range of
0.3-6.7 years. The 5-year freedom from progression to
severe stenosis was 61.2% 6 2.1% with no beneﬁt from
OMT (60.1% 6 3.7% OMT vs 61.6% 6 2.6% control;
P ¼ .33) (Fig 2). Plaque progression occurred in 262
arteries and 36 (13.7%) of these developed symptoms.
The symptomatic conversion rate in patients with plaque
progression was almost twice that of those without plaque
progression (13.7% vs 8.5%; P ¼ .02). However, plaque
progression was not a signiﬁcant predictor of INS develop-
ment in the multivariate model. The average time to plaque
progression was 32 months (range, 2-79 months). Carotid
interventions were performed in 158/262 (60%) patients
who progressed, 37 (14%) died without treatment, and
67 (26%) remain alive and untreated with respect to
a carotid intervention. Multivariate predictors of plaque
progression included CKD, aspirin use, and the use of
calcium channel blockers (Table III).
Of the entire cohort, 90 (11.3%) patients developed
INS during follow-up and 58% of these were strokes.
The average time to symptom onset was 36 months (range,
1-79 months). As stated above, 36 (40%) symptomatic
patients also showed plaque progression but the remaining
54 (60%) patients became symptomatic with a moderate
stenosis. Carotid interventions were performed in 47/90
(52%) patients who became symptomatic, 20 (22%) died
without intervention, 5 (6%) were occluded, and 18
(20%) remain without carotid intervention. The 5-year
freedom from symptoms was 88.4%6 1.5% with no beneﬁt
to OMT (85.9% 6 2.8% OMT vs 89.6% 6 1.7% control;
P ¼ .32) (Fig 3). Multivariate predictors of INS included
diabetes and warfarin, while statins were protective against
INS (Table III).
DISCUSSION
Stroke is the fourth leading cause of death in the
United States and leaves survivors with serious long-term
disability, costing an estimated $18.8 billion in direct
annual health care expenditures and incurring an indirect
cost estimated to exceed $53 billion in lost productivity.25
Up to 80% of strokes are ischemic (vs hemorrhagic), and it
is estimated that carotid stenosis >50% is seen in 12%-20%
of all patients with anterior circulation events.11 Stroke
reduction strategies have traditionally included CEA in
symptomatic and selected asymptomatic patients, although
a revisionist history of sorts has championed the viewpoint
that contemporary OMT will control carotid disease espe-
cially in asymptomatic patients such that CEA is unneces-
sary.4 The current study looked at the natural history of
patients with AMCAS in contemporary practice where
86% of the cohort was on statin therapy and 33% met target
LDL goals. It showed that medical therapy, even for
patients in whom target LDL goals were met, failed to
prevent plaque progression or the development of INS in
nearly half of the study cohort (40% plaque progression
Table I. Demographic and clinical data
Total cohort OMT No OMT P value
No. of patients 794 241 553
Demographics
Average age 72.5 6 9.2 73.7 6 8.2 72.0 6 9.6 .013
Male sex 418 (52.6) 153 (63.5) 265 (47.9) <.0001
White race 758 (95.5) 230 (95.4) 528 (95.5) .98
Comorbidities
Hypertension 613 (77.2) 207 (85.9) 406 (73.4) .0001
Diabetes 300 (37.8) 113 (46.9) 187 (33.8) .0005
Coronary artery disease 473 (59.6) 181 (75.1) 292 (52.8) <.0001
COPD 238 (30) 79 (32.8) 159 (28.7) .25
CKD 25 (3.1) 11 (4.6) 14 (2.5) .13
PVD 444 (55.9) 154 (63.9) 290 (52.4) .0028
Remote Hx ipsi symptoms 25 (3.2) 6 (2.5) 19 (3.5) .48
Contralateral occlusion 51 (6.4) 15 (6.2) 36 (6.5) .88
CKD, Chronic kidney disease; COPD, chronic obstructive pulmonary disease; Hx ipsi, history of ipsilateral; OMT, optimal medical therapy; PVD, peripheral
vascular disease.
Continuous data are presented as mean 6 standard deviation and categoric data as number (%).
Table II. Medical therapy
Total cohort, No. (%)
No. of patients 794
Antiplatelets
Aspirin (any dose) 693 (86.5)
Clopidogrel 236 (29.5)
Lipid lowering
Any agent 698 (87.1)
Statin 673 (96.4)
Other 25 (3.6)
High dose statin 133 (16.6)
LDL levels
Patients w/LDL proﬁles 594 (75)
Always >100 46 (5.7)
Always <100 306 (51.5)
Always <70 81 (13.7)
LDL, Low-density lipoprotein.
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protective against the development of INS, they did not
prevent plaque progression to a severe stenosis (>70%).
Randomized trials (speciﬁcally ACAS and ACST) sup-
porting CEA as optimal treatment of severe asymptomatic
internal carotid artery stenosis are frequently criticized with
respect to apparently inadequate therapy (by contemporary
standards) in the medical treatment arms.4,16,20 Contem-
porary criticism of ACAS is that OMT at that time con-
sisted of antiplatelet therapy with aspirin, and nurse
clinician telephone discussions regarding smoking cessation
and control of hypertension, diabetes, and lipid levels.6,26
Although it is certainly true that in the early years of the
ACST trial (enrollment began in 2003), aspirin alone was
the predominant therapy of the medial arm, these investi-
gators have emphasized that in the later years of the trial,
80% of all patients were on a statin. When the 10-year
data from this trial were analyzed, the patients were strati-
ﬁed by the use of statin therapy. Although the protective
effect of CEA from stroke was proportionately larger inpatients not on statin therapy, CEA still had a highly signif-
icant protection from stroke in patients on statin therapy.16
However, two widely quoted recent meta-analyses have
argued that the signiﬁcant advances in medical therapy
have so lowered stroke risk for asymptomatic carotid
disease that intervention is unwarranted.4,9 One criticism
of said review is the fact that the literature base quoted
contains a large percentage of patients with moderate level
carotid stenoses who would not be considered for CEA by
SVS or any other guidelines.8,18
There is a large body of evidence that supports the role
of statins in stroke prevention. The Asymptomatic Carotid
Artery Progression Study (ACAPS) found that statins low-
ered the incidence of major cardiovascular events in patients
with AMCAS compared to patients who were not on a sta-
tin.27 The Stroke Prevention by Aggressive Reduction in
Cholesterol Levels (SPARCL) trial showed that high-dose
(80 mg per day) atorvastatin led to a 16% relative risk reduc-
tion for nonfatal or fatal stroke in patients with recent stroke
or TIA.28 Then, the Justiﬁcation for the Use of Statins in
Prevention: an Intervention Trial Evaluating Rosuvastatin
(JUPITER) trial showed a 48% stroke risk reduction in
healthy patients randomized to statin over placebo.29 In
addition, there have been several meta-analyses of pooled
results from the many prospective statin trials that conﬁrmed
the beneﬁt of statins in preventing stroke.30,31 Indeed, in
the current study, the importance of statins in decreasing
symptom development was conﬁrmed and patients with
AMCAS clearly should be so treated.8,18 However, INS
occurred in some 11% of our patients on statins irrespective
of LDL target levels being achieved. This suggests that
lowering the serum LDL level may not be the most impor-
tant function of statins in the prevention of stroke.
One mechanism by which statins are thought to
prevent stroke is through their anti-inﬂammatory proper-
ties that stabilize carotid lesions and even reverse plaque
progression over time. Takaya et al performed carotid
MRI on 154 patients with symptomatic 50%-79% stenosis
Fig 1. Kaplan-Meier estimate for survival of patients stratiﬁed by
optimal medical therapy (OMT ). P value determined by Mantel-
Cox log-rank univariate analysis. The standard error at 6 years
was 2.5%.
Table III. Multivariate models of outcomes
Predictor HR CI P value
Predictors of death
Age 1.1 1.04-1.09 <.0001
Contralateral occlusion 1.9 1.1-3.3 .017
CAD 2.1 1.4-3.1 .0003
COPD 1.8 1.3-2.4 .0003
CKD 2.4 1.4-4.1 .0018
Plavix 1.7 1.2-2.3 .0026
Aspirin 0.6 0.39-0.83 .0033
Predictors of plaque progression
CKD 2.1 1.2-3.7 .009
Aspirin 1.9 1.2-3.0 .01
CCB 1.4 1.1-1.8 .007
Predictors of INS
Diabetes 2.3 1.5-3.6 .0002
Warfarin 1.9 1.2-2.9 .009
Statins (protective) 0.37 0.22-0.65 .0005
CAD, Coronary artery disease; CCB, calcium channel blocker; CI, conﬁ-
dence interval; CKD, chronic kidney disease; COPD, chronic obstructive
pulmonary disease; HR, hazard ratio; INS, ipsilateral neurologic symptoms.
Age was included in the model as a continuous variable.
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They identiﬁed neurologic events referable to the indexed
carotid artery in 12 (8%) patients and found that intrapla-
que hemorrhage was predictive of a neurologic event.32
The HIRISC study included a cohort of 120 patients
with asymptomatic carotid stenosis and 31% had a recent
plaque hemorrhage in MRI despite 88% being on a statin.33
In addition, plaque hemorrhage correlated with degree of
stenosis. These studies show that certain plaque events
(like intraplaque hemorrhage) are independent of statin
therapy. In the current study, the clinically relevant
outcome of progression of plaque to a severe stenosis wasused as a surrogate for plaque events; neither statin therapy
alone nor OMT was protective against such events.
If statins protect against stroke, is their failure to
prevent asymptomatic plaque progression from moderate
to severe diameter reduction of any consequence? Muluk
et al followed 1704 asymptomatic carotid arteries and
found that the annualized risk of progression to a higher
category by DUS was 9.3% (vs 8% in the current study),
and this progression was a predictor of neurologic events.21
Ballotta et al followed the asymptomatic contralateral
carotid arteries in 599 patients after CEA and identiﬁed
disease progression in 48% of patients with a moderate
stenosis with a mean time to progression of 18 months,
and 16% of these patients developed neurologic symp-
toms.34 Finally, the study of Sabeti et al addressed the issue
of stenosis progression and stroke risk. In a large cohort of
over a 1000 patients with 2 DUS studies just 7 months
apart these investigators noted a twofold increased risk
for stroke associated with disease progression across all
categories of initial carotid stenosis severity.22 Similarly to
the ﬁndings of Ballotta, our study indicates an actuarial pla-
que progression of 39% at 5 years with a mean time to
progression of 31 months. In addition, the symptomatic
conversion rate in patients with plaque progression was
twice that of those without. Thus, asymptomatic plaque
progression must play an important role in the eventual
development of neurologic symptoms.
Antiplatelet therapy with aspirin has long been
a cornerstone of medical therapy for stroke prevention
and is recommended for asymptomatic patients with
carotid atherosclerosis to reduce overall cardiovascular
morbidity as there is little evidence to support its efﬁcacy
in the primary prevention of stroke.4,6,20,35 In the current
study, 86% of the patients were on an aspirin. Multivariate
analysis showed that aspirin was protective against death.
This ﬁnding has been supported by a recent meta-
analysis showing that aspirin reduced the all-cause
mortality in patients with cardiovascular disease.36
However, aspirin was also predictive of disease progres-
sion, a ﬁnding that to our knowledge has not been
previously reported and the implications of which are
uncertain. One explanation for this is that the 14% who
were not on aspirin represent those with the lowest athero-
sclerotic disease burden, although there was no difference
in the incidence of contralateral severe stenoses between
the two groups.
Although SVS/AmericanHeart Association (AHA) and
American Stroke Association (ASA) guidelines recommend
smoking cessation and control of hypertension as important
components of OMT,8,18 it was impossible to determine
patient compliance with either of these recommendations
within the conﬁnes of a retrospective study design.
Adequacy of antihypertensive therapy would require veriﬁ-
cation by blood pressure measurements, which were not
routinely available, and this should be an important compo-
nent of OMT in future prospective trials. Finally, the timing
of and adherence to smoking cessation was not well docu-
mented in patient notes. Only 15% of the patient cohort
Fig 2. Kaplan-Meier estimate for freedom from plaque progres-
sion stratiﬁed by optimal medical therapy (OMT ). P value deter-
mined by Mantel-Cox log-rank univariate analysis. The standard
error at 6 years was 5.6%.
Fig 3. Kaplan-Meier estimate for freedom from ipsilateral
neurologic symptoms (INS) stratiﬁed by optimal medical therapy
(OMT ). P value determined by Mantel-Cox log-rank univariate
analysis. The standard error at 6 years was 5.0%.
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and it was impossible to accurately follow attempts at or
success with smoking cessation in this population.
Meticulous control of diabetes remains an important
component of medical therapy for AMCAS. Indeed, in
the current study, diabetes was one of the strongest predic-
tors of symptom development with a hazard ratio of 2.3.
This ﬁnding is consistent with that of Inzitari et al, who fol-
lowed the contralateral asymptomatic arteries of patients
from the NASCET study and found that a history ofdiabetes was predictive of large artery stroke in a Cox
proportional hazards model.17 In addition, the Cardiovas-
cular Health Study identiﬁed an association between
elevated fasting glucose levels and stroke risk.37 Despite its
clinical effect on stroke risk, diabetes control was not added
to OMT in this cohort because of a lack of hemoglobin A1c
levels for conﬁrmation of adequacy of treatment and it
would be inappropriate to assume that the presence of
insulin on a medication list represents adequate glucose
control. Finally, Lutz et al studied the medical management
of 95 patients after CEA and found that of the 32 patients
with diabetes, 31 (97%) had an HbA1c >6.0.38
There are several limitations that are inherent to a retro-
spective cohort study. The deﬁnition of OMT in this study
was limited to antiplatelet and statin therapy because of an
inability to conﬁrm the adequacy of the other components
of risk factor control, namely smoking cessation, and
control of hypertension and diabetes.18 LDL levels were
used to conﬁrm adequacy of statin therapy but were
unavailable in 25% of the patients on statins who were
placed in the control category. However, when these
patients were removed from the cohort, OMT did not
become signiﬁcant so they were included in the study.
There is a risk of selection bias as patients with only one
DUS were excluded from the study due to an inability to
determine plaque progression in these patients, and
patients with more comorbidities are likely to have more
regular follow-up. In addition, it is possible that patients
with limited follow-up developed INS and were treated
elsewhere such that symptomatic patients would be
under-represented in these data. Such issues would be
overcome by a prospective study of patients with asymp-
tomatic moderate stenosis that randomizes to OMT with
aggressive risk factor control vs standard medical care.
This would require a large cohort of patients over multiple
institutions, and to our knowledge, such a study is not
currently being planned.
CONCLUSIONS
The tenets of medical therapy for the prevention of
neurologic events in patients with asymptomatic carotid
stenosis have not changed in 25 years, yet the medications
used to meet these goals have changed signiﬁcantly as evi-
denced by the ACST trial where statin use increased from
around 10% at the beginning of the trial to over 80% 15
years later.16 Despite this, current medical therapy with sta-
tins was unable to halt the progression from moderate to
severe carotid stenosis or the eventual development of
neurologic symptoms in some 45% of our patients. This
failure to prevent disease progression in those withmoderate
stenoses makes it unlikely that medical therapy alone will
adequately prevent strokes in patients with >70% stenoses,
a position emphatically stated by the ACST investigators.16
The data presented herein are concordant with other retro-
spective hospital-based cohorts22 and large prospective
clinical registries,15 indicating that OMT with carotid revas-
cularization in appropriate patients remains the standard of
care in patients with asymptomatic severe carotid artery
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required to clarify the role and limitations of medical therapy
in asymptomatic carotid stenosis.AUTHOR CONTRIBUTIONS
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Supplementary Fig (online only). Breakdown of results of initial duplex ultrasound (DUS) leading to the creation of
the study cohort. CEA, Carotid endarterectomy; VS, very severe.
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